alogliptin/metformin extended release (CT-L01)
/ Celltrion
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
September 02, 2022
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 25 mg and MET XR 1,000 mg) in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Celltrion | Not yet recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
September 02, 2022
A Food Effect Study of CT-L01 After Oral Administration in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=24 | Completed | Sponsor: Celltrion | Not yet recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
September 02, 2022
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Completed | Sponsor: Celltrion | Not yet recruiting ➔ Completed
Trial completion • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
May 06, 2022
A Food Effect Study of CT-L01 After Oral Administration in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Celltrion
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
May 06, 2022
A Bioequivalence Study of CT-L01 Compared to Co-administration (ALO 12.5 mg and MET XR 500 mg) in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=48 | Not yet recruiting | Sponsor: Celltrion
New P1 trial • Diabetes • Metabolic Disorders • Type 2 Diabetes Mellitus
1 to 5
Of
5
Go to page
1